Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017 - Product Image

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017

  • ID: 4334012
  • Report
  • 161 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Achaogen Inc
  • Bayer AG
  • Lakewood-Amedex Inc
  • Melinta Therapeutics Inc
  • Nabriva Therapeutics AG
  • Shionogi & Co Ltd
  • MORE
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 7, 12, 1 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achaogen Inc
  • Bayer AG
  • Lakewood-Amedex Inc
  • Melinta Therapeutics Inc
  • Nabriva Therapeutics AG
  • Shionogi & Co Ltd
  • MORE
Introduction

Hospital Acquired Pneumonia (HAP) - Overview

Hospital Acquired Pneumonia (HAP) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development

Achaogen Inc

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Bayer AG

Cardeas Pharma Corp

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics AG

Polyphor Ltd

Sealife PHARMA GMBH

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

The Medicines Company

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Hospital Acquired Pneumonia (HAP) - Drug Profiles

(amikacin sulfate + fosfomycin) - Drug Profile

(avibactam + ceftazidime) - Drug Profile

(avibactam sodium + aztreonam lysine) - Drug Profile

(cefepime + zidebactam) - Drug Profile

(ceftolozane sulfate + tazobactam sodium) - Drug Profile

(cilastatin sodium + imipenem + relebactam) - Drug Profile

(meropenem+ vaborbactam) - Drug Profile

AA-139 - Drug Profile

Aerucin - Drug Profile

alalevonadifloxacin - Drug Profile

amikacin sulfate - Drug Profile

arbekacin - Drug Profile

ASN-100 - Drug Profile

cefiderocol - Drug Profile

delafloxacin meglumine - Drug Profile

EBX-004 - Drug Profile

eravacycline - Drug Profile

exeporfinium chloride - Drug Profile

fosfomycin tromethamine - Drug Profile

iclaprim mesylate - Drug Profile

lefamulin acetate - Drug Profile

levonadifloxacin - Drug Profile

MEDI-3902 - Drug Profile

Mul-1867 - Drug Profile

murepavadin - Drug Profile

Nu-2 - Drug Profile

Nu-3 - Drug Profile

Panaecin - Drug Profile

panobacumab - Drug Profile

plazomicin sulfate - Drug Profile

POL-7001 - Drug Profile

Qn-2251 - Drug Profile

SLP-0905 - Drug Profile

sodium hypochlorite - Drug Profile

suvratoxumab - Drug Profile

tedizolid phosphate - Drug Profile

telavancin hydrochloride - Drug Profile

tosatoxumab - Drug Profile

Viritron VDX - Drug Profile

Hospital Acquired Pneumonia (HAP) - Dormant Projects

Hospital Acquired Pneumonia (HAP) - Discontinued Products

Hospital Acquired Pneumonia (HAP) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H2

Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H2

Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2

Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2

Number of Products under Development by Companies, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Achaogen Inc
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Bayer AG
  • Cardeas Pharma Corp
  • Destiny Pharma Ltd
  • Dong-A Socio Holdings Co Ltd
  • Lakewood-Amedex Inc
  • MedImmune LLC
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Polyphor Ltd
  • Sealife PHARMA GMBH
  • Shionogi & Co Ltd
  • Tetraphase Pharmaceuticals Inc
  • The Medicines Company
  • Theravance Biopharma Inc
  • Wockhardt Ltd
  • Zavante Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll